[Federal Register Volume 87, Number 19 (Friday, January 28, 2022)]
[Notices]
[Page 4629]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01746]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2022-1 Phase 
I: Adjuvant Development for Vaccines and for Autoimmune and Allergic 
Diseases (Topic 105).
    Date: February 18, 2022.
    Time: 10:00 a.m. to 1:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G51, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Thomas F. Conway, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G51, 
Rockville, MD 20852, 240-507-9685, <a href="/cdn-cgi/l/email-protection#33475b5c5e52401d505c5d44524a735d5a5b1d545c45"><span class="__cf_email__" data-cfemail="2e5a4641434f5d004d4140594f576e40474600494158">[email protected]</span></a>.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2022-1 Phase 
II: Adjuvant Development for Vaccines and for Autoimmune and 
Allergic Diseases (Topic 105).
    Date: February 18, 2022.
    Time: 1:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G51, 
Rockville, MD 20892 (Virtual Meeting).
    Contact Person: Thomas F. Conway, Ph.D., Scientific Review 
Officer, Scientific Review, Program Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G51, 
Rockville, MD 20852, 240-507-9685, <a href="/cdn-cgi/l/email-protection#55213d3a3834267b363a3b22342c153b3c3d7b323a23"><span class="__cf_email__" data-cfemail="add9c5c2c0ccde83cec2c3daccd4edc3c4c583cac2db">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: January 25, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-01746 Filed 1-27-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>